Peps
What is Mazdutide?
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight management. GLORY-1 tested it in Chinese adults with overweight or obesity.
Biological role or research focus
Weight-management research.
The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.
Role reference: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
Names you may encounter
IBI362 · LY3305677
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Dual GLP-1 / glucagon receptor agonist
- Research focus
- Weight-management research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
Molecular structure
How Mazdutide works
Its design combines incretin signaling with glucagon-receptor activity. Clinical trials test whether this combination produces weight changes with an acceptable adverse-event profile; the receptor combination alone cannot establish superiority over another medicine.
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
Clinical context & research status
This page examines the GLORY-1 publication. Regulatory status must be checked for the exact product and country. A trial preparation and a supplier’s research-use product are not interchangeable.
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2025
GLORY-1
How did weight change versus placebo in GLORY-1?
- Population / model
- 610 Chinese adults aged 18–75 with obesity, or overweight and an associated condition.
- Study design
- Randomized placebo-controlled phase 3 study with two mazdutide groups; 48-week follow-up.
- Main finding
- At week 32, mean weight change was −10.09% and −12.55% in the mazdutide groups versus +0.45% with placebo. At week 48, the corresponding changes were −11.00%, −14.01%, and +0.30%.
- Limits & context
- The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Emerging pharmacotherapies for obesity: A systematic review. ↗
Pharmacological reviews · 2025 Jan · Journal Article, Systematic Review
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials. ↗
Metabolism: clinical and experimental · 2024 Dec · Journal Article, Systematic Review, Network Meta-Analysis, Research Support, Non-U.S. Gov't
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis. ↗
BMJ (Clinical research ed.) · 2026 Jul 8 · Systematic Review, Network Meta-Analysis, Journal Article, Comparative Study
Mazdutide: First Approval. ↗
Drugs · 2025 Dec · Journal Article, Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Gastrointestinal adverse events were mostly mild or moderate in this study. Discontinuation due to adverse events occurred in 1.5%, 0.5%, and 1.0% of the respective groups. These figures do not resolve rare or long-term harms.
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
Identity, route, and evidence limits
The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
1 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Biohackingturkey
Mazdutide Nedir? Zayıflamada Yeni Dönem Başlıyor! ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Can these results rank all weight-management peptides?
- What population, comparator, and route were actually studied?
- The study population and analysis are specific to this trial. It was not a head-to-head comparison with semaglutide or tirzepatide. The trial was funded by Innovent.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Can these results rank all weight-management peptides?
No. Comparisons across separate trials can differ because of population, duration, comparator, and analysis. A direct comparative trial answers a different question.
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. · 2025 ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.